Marshall Gunnell is a Tokyo-based tech journalist and editor with over a decade of experience covering IT, cybersecurity and data storage. Alongside CNET, his work has appeared in ZDNET, Business ...

MORRISVILLE, N.C., Oct. 24, 2025 (GLOBE NEWSWIRE) -- 374Water Inc. (NASDAQ: SCWO) (“374Water” or the “Company”), a global leader in organic waste destruction technology and services for the industrial ...

October 2025 – In today’s data-driven world, secure and reliable online access has become essential for businesses, marketers, and developers. Recognizing this growing demand, Twinstrata has emerged ...

Julia Kagan is a financial/consumer journalist and former senior editor, personal finance, of Investopedia. Thomas J Catalano is a CFP and Registered Investment Adviser with the state of South ...

Oct 20 (Reuters) - Proxy firm Glass Lewis has recommended that Tesla (TSLA.O), opens new tab shareholders vote against the proposed $1 trillion pay package for CEO Elon Musk, days after ISS also urged ...

Globals Showcases MarCAP, a Tactical SOC-in-a-Box for Naval Cyber Defence, at Indian Navy's Seminar on Impact of Cyber Attacks on Maritime Sector ...

Investor Cathie Wood, a longtime Tesla bull known for first investing in the company a decade ago at $13 per share, condemned the growing resistance to Tesla CEO Elon Musk’s potential $1 trillion pay ...

Roger is a long-time tech journalist with many site credits including AppleInsider and Android Authority. His specialties include everything from Apple, Android, and Windows devices through to ...

Religare Enterprises (REL) is planning to bring its unlisted insurance arm, Care Health Insurance, onto its books via a reverse merger through a preferential share issue, according to people familiar ...

Diabetes is a chronic, (mostly) irreversible condition, in which the body has high blood sugar because it doesn't produce enough insulin, or can't use it effectively. Those who suffer from Diabetes, ...

Scientists may have found a way to address age-related vision changes. A new mouse study IDs a treatment to help. The treatment needs to be tested on humans, but eye doctors find the study promising.